Probiodrug
Appoints Mark Booth as Chief Business Officer
Expands Management Board with Senior Hire
HALLE/SAALE,
Germany, 23 March 2016 - Probiodrug AG (Euronext
Amsterdam: PBD), a biopharmaceutical company developing novel
therapeutic solutions to treat Alzheimer's disease, today announced
that Mark Booth has joined the company as Chief Business Officer
and member of the Management Board. Mr. Booth brings over 30
years of biopharmaceutical experience to Probiodrug.
"Mark's broad business background
and proven track record make him a valuable addition to our
management board," said Dr. Erich Platzer, Chairman of the
Supervisory Board of Probiodrug. "His extensive experience in
business development and investor relations will be instrumental to
propel Probiodrug's strategy internationally and in particular the
United States."
"I am excited to be joining
Probiodrug," added Mark Booth. "This is truly a unique
opportunity and I look forward to working with the team as we
advance new and novel therapeutic treatments for Alzheimer's
patients."
Mark Booth most recently served as
the Chief Commercial Officer at Orexigen Therapeutics, Inc.
where he also played a leadership role in all business
development and investor relations activities.
Prior to Orexigen Therapeutics,
Inc., Mr. Booth served as the President of Takeda Pharmaceuticals
North America (TPNA). Under his leadership TPNA became one of
the fastest growing pharmaceutical companies in the U.S. with sales
of over $4 billion. Prior to his role at TPNA, Mr. Booth was the
Senior Vice President, General Manager at Immunex
Corporation. Previously, Mr. Booth was at Abbott Laboratories
where he held multiple positons, in his last role at Abbott, he
held the title of Division Vice President, General Manager for the
anti-infective franchise.
Mr. Booth holds a BS in Biology
from Northern Illinois University and an MBA from Northwestern
University Kellogg School of Management.
###
For more
information, please contact:
Probiodrug
Dr Konrad Glund, CEO
Email: contact@probiodrug.de
Hume
Brophy
Mary Clark, Supriya Mathur, Eva Haas
Tel: +44 (0) 20 7862 6475
Email: probiodrug@humebrophy.com
The Trout
Group
Tricia Truehart
Tel: +1 (646) 378-2953
Email: ttruehart@troutgroup.com
Notes to
Editors:
About Probiodrug AG
Headquartered in Halle, Germany, Probiodrug AG (Euronext Amsterdam:
PBD) is a biopharmaceutical company focused on the development of
new therapeutic products for the treatment of Alzheimer's
disease.
Founded in 1997, the company
successfully developed a novel therapeutic concept for diabetes -
the DP4 inhibitors - which provided the basis for a novel class of
antidiabetics - the gliptins. Its core capabilities are based on
its long-standing expertise in the elucidation of the structure and
function of enzymes involved in the modification of proteins and
peptides, which play a central role in pathological conditions.
Today Probiodrug's aim is to
become a leading company in the development of Alzheimer's disease
treatments and to thereby provide a better life for Alzheimer's
disease patients. It has identified a new therapeutic concept
linked to disease initiation and progression. The development
approaches are targeting pyroglutamate-Abeta (pGlu-Abeta) as a
therapeutic strategy to fight Alzheimer's disease. The Company has
medical use and composition of matter patents related to the
inhibition of Glutaminyl Cyclase (QC) and anti-pGlu-Abeta- specific
monoclonal antibodies, providing it, in the Company's view, with a
leading position in this field of research.
www.probiodrug.de
About Alzheimer's
disease
Alzheimer's disease is a neurological disorder, which is the most
common form of dementia, and ultimately leads to death. Because
Alzheimer's disease cannot be cured and is degenerative, the
affected patients must increasingly rely on others for assistance.
Today, over 46 million people worldwide currently live with the
condition and this number is expected to increase to 132 million by
2050. Alzheimer's also has an estimated, global societal cost of
US$ 818 billion (World Alzheimer Report 2015).
Forward Looking
Statements
Information set forth in this press release
contains forward-looking statements, which involve a number of
risks and uncertainties. The forward-looking statements contained
herein represent the judgment of Probiodrug AG as of the date of
this press release. Such forward-looking statements are neither
promises nor guarantees, but are subject to a variety of risks and
uncertainties, many of which are beyond our control, and which
could cause actual results to differ materially from those
contemplated in these forward-looking statements. We expressly
disclaim any obligation or undertaking to release publicly any
updates or revisions to any such statements to reflect any change
in our expectations or any change in events, conditions or
circumstances on which any such statement is based.